P. Wannamaker

发表

Unexpected Finding of Delayed-Onset Seizures in HIV-Positive, Treatment-Experienced Subjects in the Phase Iib Evaluation of Fosdevirine (Gsk2248761)

J. Eron, E. Dejesus, D. Margolis, 2014, Antiviral therapy.

Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients

K. Squires, E. Dejesus, B. Young, 2010, HIV clinical trials.

A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.

M. Watson, R. Cuffe, P. Wannamaker, 2009, AIDS patient care and STDs.

Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial

C. Farthing, M. Fischl, N. Bellos, 2003, Pharmacotherapy.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

D. Fine, Kimberly Smith, N. Bellos, 2009, AIDS.

The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy–Naive HIV-1-Infected Patients

G. Gray, J. Nadler, P. Wannamaker, 2004, Journal of acquired immune deficiency syndromes.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

K. Squires, E. Dejesus, N. Bellos, 2010, AIDS.

High sensitivity of HLA-B*5701 in Whites and Blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR)

S. Mallal, M. Saag, E. Phillips, 2007 .

Similar Virologic and Immunologic Efficacy With Fosamprenavir Boosted With 100 mg or 200 mg of Ritonavir in HIV-Infected Patients: Results of the LESS Trial

A. LaMarca, C. Cohen, E. Dejesus, 2010, HIV clinical trials.

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

C. Katlama, S. Staszewski, J. Eron, 2006, The Lancet.

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

S. Mallal, M. Saag, E. Phillips, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Increased HIV infection rate among violent deaths: a mortuary study in the Republic of Congo

K. Squires, D. Berger, E. Dejesus, 2008, AIDS (London).

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men

Hongzhou Lu, B. Zhu, W. Spreen, 2022, Antimicrobial agents and chemotherapy.

A prospective, 96‐week study of the impact of Trizivir®, Combivir®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity

K. Tashima, D. Averitt, G. E. Pakes, 2006, HIV medicine.

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

L. Bekker, R. Wood, C. Orrell, 2008, AIDS.